Cited by 294Genetics and Neurodevelopmental DisordersNeuroscience and Neuropharmacology ResearchEpilepsy research and treatment

The GABAA Receptor as a Therapeutic Target for Neurodevelopmental Disorders

Open access
Braat, Sien, Kooy, R. Frank·2015·Neuron

Abstract

Intellectual disability, autism spectrum disorder, and epilepsy are prime examples of neurodevelopmental disorders that collectively affect a significant percentage of the world population. Recent technological breakthroughs allowed the elucidation of the genetic causes of many of these disorders. As neurodevelopmental disorders are genetically heterogeneous, the development of rational therapy is extremely challenging. Fortunately, many causative genes are interconnected and cluster in specific cellular pathways. Targeting a common node in such a network would allow us to interfere with a series of related neurodevelopmental disorders at once. Here, we argue that the GABAergic system is disturbed in many neurodevelopmental disorders, including fragile X syndrome, Rett syndrome, and Dravet syndrome, and is a key candidate target for therapeutic intervention. Many drugs that modulate the GABAergic system have already been tested in animal models with encouraging outcomes and are readily available for clinical trials.

Integrity signals

Registry

Crossref · 10.1016/j.neuron.2015.03.042

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Widespread defects in GABAergic signaling across cortical and subcortical regions may also contribute to the abnormal hyperexcitability of juvenile Fmr1 mutants.

    “In addition, widespread defects in GABAergic signaling across cortical and subcortical regions may also contribute to the abnormal hyperexcitability of juvenile Fmr1 mutants 107 .”
  • Defects in GABAergic signaling may also contribute to the hyperexcitability observed in Fmr1 mutant mice.

    “defects in GABAergic signaling may also contribute to the hyperexcitability observed in Fmr1 mutant mice 107 .”
  • Treatment with GABAA and GABAB receptor modulators seems to control hyperexcitability in Fmr1 mutant mice, but similar approaches in human patients have failed to yield positive outcomes.

    “Similarly, treatment with GABAA and GABAB receptor modulators seems to control hyperexcitability in Fmr1 mutant mice, but similar approaches in human patients have failed to yield positive outcomes 107,116 .”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Braat, S., & Kooy, R. F.
Affiliations
University of Antwerp (BE)
Corresponding author
Kooy, R. Frank
Venue
Neuron
Publisher
Elsevier BV
Published
2015-06
Volume
86
Issue
5
Pages
1119-1130
ISSN
0896-6273 (ISSN-L)
OpenAlex
W1485428340
Cited by
294
References
19
Citations by year
2026: 11 · 2025: 24 · 2024: 17 · 2023: 31 · 2022: 36 · 2021: 30 · 2020: 30 · 2019: 27 · 2018: 31 · 2017: 28 · 2016: 24 · 2015: 5
FWCI
3.79
Type
journal article
Language
en
Open access
Locations
  • Neuron (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • FRAXA Research Foundation
  • Marinus Pharmaceuticals
  • Fonds Wetenschappelijk Onderzoek
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Epilepsy research and treatment
Keywords
GABAA receptor, neurodevelopmental disorders, GABAergic system, fragile X syndrome, Rett syndrome, Dravet syndrome, autism spectrum disorder, intellectual disability, epilepsy, therapeutic target, GABAergic drugs, genetic heterogeneity
MeSH terms
Animals, Developmental Disabilities, Child Development Disorders, Pervasive, Fragile X Syndrome, Humans, Nervous System Diseases, Receptors, GABA-A, Rett Syndrome, Drug Delivery Systems, GABA Modulators

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review